Trial Profile

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemarituzumab (Primary)
Indications Biliary cancer; Bladder cancer; Carcinoma; Colorectal cancer; Gastric cancer; Lung cancer; Lymphoma; Oesophageal cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Five Prime Therapeutics

Most Recent Events

13 Mar 2020 Results published in the Journal of Clinical Oncology
13 Mar 2020 Results published in a Five Prime Therapeutics media release.
13 Mar 2020 According to a Five Prime Therapeutics media release,data published in the digital edition of the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com